ClinicalTrials.gg
CompletedNCT02255045Updated May 3, 2019

Assessment of a Vaginal Ring With Meloxicam in the Treatment of Dysmenorrhea

A Phase 2/3 interventional study of Meloxicam and Diclofenac Potassium in Dysmenorrhea, sponsored by Laboratorios Andromaco S.A.. Completed at 1 site in Chile. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-03.

Sponsored by Laboratorios Andromaco S.A. (part of Grünenthal GmbH) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The investigators propose that the sustained administration of a vaginal ring would have a better response with respect to pain and a better safety profile than the oral administration of a non-steroidal anti-inflammatory drug.

To assess the relief of the symptoms associated with dysmenorrhea, a specific survey was elaborated that also includes a Visual Analog Scale (VAS) to objectify and measure dysmenorrhea as is the case with McGill's Pain Questionnaire (MPQ).

02

Conditions studied

  • Dysmenorrhea

Browse trials for

03

In context

Dysmenorrhea

432 studies on the registry are indexed under Dysmenorrhea; 109 are open to participants now.

This study's enrollment of 68 is close to the median of 62 across 364 interventional studies indexed under Dysmenorrhea.

Browse Dysmenorrhea studies →

Lead sponsor

Laboratorios Andromaco S.A. is the lead sponsor of 19 studies on the registry; none are open to participants now.

First submitted after Laboratorios Andromaco S.A. became part of Grünenthal GmbH.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Regular menstrual cycles on previous 3 months (24-35 days),
  • Primary dysmenorrhea on 3 previous months,
  • With tubal ligation or users of condom for ,
  • of at least 11 g/dl,
  • Safety blood analysis in normal levels

Exclusion criteria

Exclusion Criteria:

  • Secondary dysmenorrhea,
  • Users of hormonal (2 months prior to the study) or intrauterine devices (IUDs) (1 month prior the study).
  • Allergy to any anti-inflammatory drug including meloxicam or diclofenac.
  • Allergy to silicon.
  • Pregnant or in lactation.
  • Women with untreated or decompensated endocrine disorders
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Dose 1 of meloxicam in vaginal ring

    2.4 g of meloxicam in a vaginal ring

    Drug: Meloxicam · Drug: Placebo Oral

  • Experimental
    Dose 2 of meloxicam in vaginal ring

    3.0 g of meloxicam in a vaginal ring

    Drug: Meloxicam · Drug: Placebo Oral

  • Active comparator
    Oral non-steroidal anti-inflammatory drug

    Diclofenac potassium

    Drug: Diclofenac Potassium · Drug: Placebo Vaginal

  • Placebo comparator
    Placebo vaginal ring and oral pill

    Placebo vaginal ring and placebo oral pill

    Drug: Placebo Oral · Drug: Placebo Vaginal

Interventions

  • 1 Meloxicam Vaginal Ring (MVR) for 4-6 days

  • 1 tablet 50 mg diclofenac every 12 hours for 4-6 days

  • DrugPlacebo Oral

    1 placebo tablet every 12 hours for 4-6 days

  • DrugPlacebo Vaginal

    1 placebo vaginal ring for 4-6 days

06

What researchers measure

Primary outcomes

  1. Efficacy: Percentage of primary dysmenorrhea reduction

    Change in primary dysmenorrhea using the VAS (0 = pain-free, 10 = maximum pain intensity) for the vaginal ring with meloxicam used during the perimenstrual period compared with a placebo ring.

    Time frame: 5 months

Secondary outcomes

  1. Minimum effective dose of meloxicam

    Determine the minimum effective dose of the vaginal ring with meloxicam in primary dysmenorrhea using a survey. This survey includes a VAS (0 = pain-free, 10 = maximum pain intensity) to evaluate pain intensity, questions about the pain type (superficial, deep), pain location (diffuse, localized), pain duration (for a moment, intermittent, constant), location in the abdominal or back region (yes/no), and the presence of breast pain, thigh pain, mood changes, mastalgia, gastrointestinal disorders, abdominal distension, headache, dizziness, or acne (all with yes/no responses). Furthermore, the survey includes quality of life assessments (effects on routine activity, on work activity and/or housework, social and recreational activities, family and/or interpersonal relationships, state of mind, and sleep quality: 0 = no negative effect, 10 = maximum negative effect).

    Time frame: 5 months

  2. Efficacy: Comparison of meloxicam vaginal ring and oral diclofenac

    Compare the effect of a vaginal ring with meloxicam versus the oral administration of a non-steroidal anti-inflammatory drug commonly used for primary dysmenorrhea during one menstrual cycle, using a survey. This survey includes a VAS (0 = pain-free, 10 = maximum pain intensity) to evaluate pain intensity, questions about the pain type (superficial, deep), pain location (diffuse, localized), pain duration (for a moment, intermittent, constant), location in the abdominal or back region (yes/no), and the presence of breast pain, thigh pain, mood changes, mastalgia, gastrointestinal disorders, abdominal distension, headache, dizziness, or acne (all with yes/no responses). Furthermore, the survey includes quality of life assessments (effects on routine activity, on work activity and/or housework, social and recreational activities, family and/or interpersonal relationships, state of mind, and sleep quality: 0 = no negative effect, 10 = maximum negative effect).

    Time frame: 5 months

07

Study locations

1 site
  • Instituto Chileno de Medicina Reproductiva (ICMER)
    Santiago, 8320165, Chile
08

References and documents

Publications

  • Marjoribanks J, Proctor M, Farquhar C, Derks RS. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD001751. doi: 10.1002/14651858.CD001751.pub2. PubMed 20091521 ↗
  • Harel Z. Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhea. J Pediatr Adolesc Gynecol. 2004 Apr;17(2):75-9. doi: 10.1016/j.jpag.2004.01.002. PubMed 15050982 ↗
  • de Mello NR, Baracat EC, Tomaz G, Bedone AJ, Camargos A, Barbosa IC, de Souza RN, Rumi DO, Martinez Alcala FO, Velasco JA, Cortes RJ. Double-blind study to evaluate efficacy and safety of meloxicam 7.5 mg and 15 mg versus mefenamic acid 1500 mg in the treatment of primary dysmenorrhea. Acta Obstet Gynecol Scand. 2004 Jul;83(7):667-73. doi: 10.1111/j.0001-6349.2004.00433.x. PubMed 15225193 ↗
  • Chantler I, Mitchell D, Fuller A. The effect of three cyclo-oxygenase inhibitors on intensity of primary dysmenorrheic pain. Clin J Pain. 2008 Jan;24(1):39-44. doi: 10.1097/AJP.0b013e318156dafc. PubMed 18180635 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2014 to primary completion in Feb 2016, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2014
First posted
Oct 2, 2014
StartActual
Jun 27, 2014
Primary completionActual
Feb 21, 2016
CompletionActual
Mar 16, 2016
Last update
May 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02255045
Responsible party
Sponsor
First posted
Oct 2, 2014
Start date
Jun 27, 2014
Primary completion
Feb 21, 2016
Completion
Mar 16, 2016
Last update
May 3, 2019

Study contacts

Grünenthal Study Director
study director · Grünenthal GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meloxicam

Start the discussion